New antibody drug targets Hard-to-Treat brain tumors
NCT ID NCT05916313
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This early-stage trial tests a new drug, BI 764532, in adults with a type of brain tumor (glioma) that has a specific marker called DLL3. The drug is designed to help the body's immune cells attack the tumor. The main goal is to find the highest dose that is safe, and to see if it can control the disease. About 18 people whose previous treatments stopped working will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cantonal Hospital of Aarau
Aarau, CH-5001, Switzerland
-
Erasmus Medisch Centrum-ROTTERDAM-50697
Rotterdam, 3015 GD, Netherlands
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
Klinikum der Universität München AÖR
München, 81377, Germany
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Salzburg Cancer Research Institute
Salzburg, 5020, Austria
-
University Hosp. Zurich
Zurich, 8901, Switzerland
-
University Hospital of Lausanne
Lausanne, 1101, Switzerland
-
University of California Irvine
Orange, California, 92868, United States
-
Universitätsklinikum Frankfurt
Frankfurt, 60596, Germany
-
Universitätsklinikum Tübingen
Tübingen, 72076, Germany
Conditions
Explore the condition pages connected to this study.